14 results
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
.
Besides relying on patents, we also rely on trade secrets, proprietary know-how and continuing innovation to develop and maintain our competitive position … know-how and any continuing innovation, in part, through confidentiality and proprietary information agreements. However, these agreements may
8-K
EX-99.1
MIRA
Mira Pharmaceuticals Inc
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
agreement and obtaining initial funding for development through the MIRALOGX line of credit propels MIRA into an exciting phase of innovation
424B4
MIRA
Mira Pharmaceuticals Inc
4 Aug 23
Prospectus supplement with pricing info
1:01pm
and continuing innovation to develop and maintain our competitive position, especially when we do not believe that patent protection is appropriate or can … be obtained. We seek protection of these trade secrets, proprietary know-how and any continuing innovation, in part, through confidentiality
424B1
MIRA
Mira Pharmaceuticals Inc
4 Aug 23
Prospectus with pricing info
12:59pm
to manufacture MIRA1a.
Besides relying on patents, we also rely on trade secrets, proprietary know-how and continuing innovation to develop and maintain our … secrets, proprietary know-how and any continuing innovation, in part, through confidentiality and proprietary information agreements. However
S-1
EX-10.4
vv0ei4t411mfvgf3
29 Jun 23
IPO registration
4:39pm
S-1
5f5ws7x3c5 pi
29 Jun 23
IPO registration
4:39pm
DRS/A
EX-10.4
ehrru2
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
86akv
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
x8td53yi1
2 May 23
Draft registration statement (amended)
12:00am
DRS
rf010121c
29 Jun 22
Draft registration statement
12:00am
- Prev
- 1
- Next